AXSMのチャート
AXSMの企業情報
| symbol | AXSM |
|---|---|
| 会社名 | Axsome Therapeutics Inc （アクサム・セラピュ―ティクス） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 Axsome Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies for the management of central nervous system (CNS) disorders including pain. It operates in the business of developing novel therapies for the management of CNS disorders segment. Its product candidate AXS-02 (disodium zoledronate tetrahydrate) is an oral targeted non opioid therapeutic for chronic pain. It is developing AXS 02 for the treatment of pain in over three conditions such as complex regional pain syndrome (CRPS); knee osteoarthritis (OA) associated with bone marrow lesions (BMLs) and chronic low back pain (CLBP) associated with type I or mixed type I and type II Modic changes (MCs). Its product candidate AXS 05 is a fixed dose combination of dextromethorphan (DM) and bupropion. It is developing AXS 05 for the treatment of over two conditions such as treatment resistant depression (TRD) and agitation in patients with Alzheimer''s disease (AD). アクサム・セラピュ―ティクスは米国のバイオ医薬品企業。臨床段階で、痛みと中枢神経系障害のための治療法の開発に従事。医薬品候補の「AXS-02」は非オピオイドの経口薬で、慢性的な痛みの治療に使用される。また「AXS-05」はデキストロメトルファンとブプロピオンの一定量を組み合わせた革新的な治療薬である。本社はニューヨーク。 Axsome Therapeutics, Inc. is a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders for which there are limited treatment options. For the many people facing unsatisfactory treatments for CNS disorders, Axsome accelerates the invention and adoption of life-changing medicines. Axsome's core CNS product candidate portfolio includes five clinical-stage candidates, AXS-05, AXS-07, AXS-09, AXS-12, and AXS-14. AXS-05 is being developed for major depressive disorder (MDD), Alzheimer's disease (AD) agitation, and as a treatment for smoking cessation. AXS-07 is being developed for the acute treatment of migraine. AXS-12 is being developed for the treatment of narcolepsy. AXS-14 is being developed for fibromyalgia. AXS-05, AXS-07, AXS-09, AXS-12, and AXS-14 are investigational drug products not approved by the FDA. |
| 本社所在地 | 25 Broadway 9th Floor New York NY 10004 USA |
| 代表者氏名 | Herriot Tabuteau Herriot Tabuteau |
| 代表者役職名 | Chairman of the Board Chief Executive Officer 取締役会長兼最高経営責任者 |
| 電話番号 | +1 212-203-5072 |
| 設立年月日 | 40909 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2015年 |
| 従業員数 | 25人 |
| url | www.axsome.com |
| nasdaq_url | https://www.nasdaq.com/symbol/axsm |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -27.84864 |
| 終値（lastsale） | 3.39 |
| 時価総額（marketcap） | 88997202.18 |
| 時価総額 | 時価総額（百万ドル） 93.50153 |
| 売上高 | 売上高（百万ドル） 0.00000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 81.62078 |
| 当期純利益 | 当期純利益（百万ドル） -26.95052 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Axsome Therapeutics Inc revenues was not reported. Net loss decreased 13% to $13.1M. Lower net loss reflects Research and development - Other decrease of 6% to $10.1M (expense) Stock-based Compensation in SGA decrease of 9% to $788K (expense) Stock-based Compensation in R&D decrease of 21% to $221K (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$0.71 to -$0.51. |
AXSMのテクニカル分析
AXSMのニュース
Axsome Therapeutics''s Return On Capital Employed Insights 2022/11/30 14:48:22 Benzinga
Benzinga Pro data, Axsome Therapeutics (NASDAQ: AXSM ) reported Q3 sales of $16.85 million. Earnings fell to a loss of $44.82 million, resulting in a 8.17% decrease from last quarter. Axsome Therapeutics collected $8.82 million in revenue during Q2, but reported earnings showed a $41.44 million loss. What Is ROCE? Earnings data without context is not clear and can be difficult to base trading decisions on. Return on Capital Employed (ROCE) helps to filter signal from noise by measuring yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth of a company … Full story available on Benzinga.com
A closer look at Axsome Therapeutics Inc. (AXSM) is warranted 2022/11/29 13:00:00 US Post News
Axsome Therapeutics Inc. (NASDAQ:AXSM) marked $74.74 per share on Monday, up from a previous closing price of $56.82. While Axsome Therapeutics Inc. has overperformed by 31.54%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, AXSM rose by 102.44%, with highs and lows ranging from $71.98 to […]
China''s #COVID Issues & Fed Fears Pressure Monday''s Stock Market - $ADT $AXSM $KDNY $TSLA $VIX Rise! - Vista Partners LLC 2022/11/28 22:48:01 Vista Partners
Quote of the Day — “What you do today can improve all your tomorrows.” – Ralph Marston Happy Monday! I hope that you had a great start to the week and that you are preparing to support the US Men’s National Soccer Team during their World Cup match tomorrow, Tuesday at 2pm ET when they square off […]
10 Things to Know as Tesla Revamps Model 3 With Project ‘Highland’ 2022/11/28 18:21:57 InvestorPlace
Source: Khairil Azhar Junos/Shutterstock.com Recent reports claim that Tesla (NASDAQ: TSLA ) is planning to revamp the Model 3 under the secret “Highland” project. The Tesla Model 3 was first introduced back in 2017 as a more economic option for cost-minded consumers. Since then, the electric vehicle (EV) hasn’t been given any major updates and its age is starting to show. That’s reportedly why a revamp of the Tesla Model 3 is underway as Project Highland. Let’s get into everything fans of Tesla, as well as TSLA stock investors, need to know about that below! Tesla Model 3 Revamp According to the latest reports, Tesla is aiming to launch the updated Model 3 as early as next year. The goal of this redesign is to simplify the interior design while also retaining features that Tesla owners love. That includes removing some of the more complex moving parts while still keeping the Tesla display. This would allow Tesla to reduce the costs of the Model 3, which makes sense considering the effects inflation is having on markets.
Why Taboola Shares Are Trading Higher By Around 53%? Here Are 53 Stocks Moving In Monday''s Mid-Day Session 2022/11/28 18:01:49 Benzinga
Gainers Taboola.com Ltd. (NASDAQ: TBLA ) shares gained 52.5% to $2.8050 after the company announced it entered into a 30-year exclusive commercial agreement with Yahoo. Digital Brands Group, Inc. (NASDAQ: DBGI ) shares jumped 47.8% to $8.81. The company recently posted a rise in Q3 revenue. NanoVibronix, Inc. (NASDAQ: NAOV ) gained 39% to $0.3599. NanoVibronix recently announced interim results of its U.K. clinical study for UroShield, a disposable ultrasound device that reduces biofilm contaminating the catheter surface. Talkspace, Inc. (NASDAQ: TALK ) shares climbed 34.3% to $0.8055. Talkspace recently named Jon Cohen as CEO. Studio City International Holdings Limited (NYSE: MSC ) gained 33% to $2.70. Helbiz, Inc. (NASDAQ: HLBZ ) rose 31.8% to $0.3032 after gaining more than 21% on Friday. Axsome Therapeutics, Inc. (NASDAQ: AXSM ) climbed 31.4% to $74.71 after the company announced AXS-05 achieved its primary endpoint in the ACCORD Phase 3 trial in Alzheimer''s disease agitation. Tricida, Inc. (NASDAQ: TCDA ) rose 25.3% to $0.2577 after gaining over 6% on Friday.
Axsome Therapeutics Inc. (NASDAQ: AXSM)’S Stock Adds 0.35%, But It May Make Sense To Invest. 2022/10/18 12:00:00 Stocks Register
Axsome Therapeutics Inc. (NASDAQ:AXSM) price closed higher on Monday, October 17, jumping 0.35% above its previous close. A look at the daily price movement shows that the last close reads $48.00, with intraday deals fluctuated between $47.6101 and $50.00. The company’s 5Y monthly beta was ticking 2.06. Taking into account the 52-week price action we … Axsome Therapeutics Inc. (NASDAQ: AXSM)’S Stock Adds 0.35%, But It May Make Sense To Invest. Read More »
Axsome Therapeutics Inc. (NASDAQ: AXSM) Is Rated A Buy By Analysts. 2022/10/17 14:00:00 Marketing Sentinel
In the last trading session, 1.91 million Axsome Therapeutics Inc. (NASDAQ:AXSM) shares changed hands as the company’s beta touched 1.84. With the company’s per share price at $48.00 changed hands at $1.79 or 3.87% during last session, the market valuation stood at $1.86B. AXSM’s last price was a discount, traded about -49.96% off its 52-week … Axsome Therapeutics Inc. (NASDAQ: AXSM) Is Rated A Buy By Analysts. Read More »
COLA 2023: How Much Did Social Security Benefits Increase for 2023? 2022/10/13 16:11:58 InvestorPlace
Source: Shutterstock / Lane V. Erickson Social Security benefits are increasing for 2023 as the Social Security Administration announces an update to the Cost-of-Living Adjustment (COLA) . The COLA 2023 update will see receivers of Social Security get an 8.7% increase. The Social Security Administration came to this decision after evaluating the increases in the Consumer Price Index ( CPI ) over the last 12 months. To put that increase in perspective, the average monthly retiree benefit is increasing by $144 . Also, those receiving benefits will note that the 8.7% increase comes after an 8.2% increase in the CPI over the prior year. Dan Adcock, the director of government relations and policy at the National Committee to Preserve Social Security and Medicare, told CNBC the following about the COLA 2023 update. “The COLAs really are about people treading water; they’re not increases in benefits. They’re more trying to provide inflation protection so that people can maintain their standard of living.” When Will the COLA 2023 Increase Go Into Effect?
Why Is Axsome Therapeutics (AXSM) Stock Up Today? 2022/10/13 15:46:57 InvestorPlace
Sometimes, company shares can catch a bid when a rival gets bad news. That''s happening with Axsome today as AXSM stock moves higher.
Relmada Tanks After ''Paradoxical Results'' Undermine Depression Drug; Axsome Surges 2022/10/13 13:25:40 Investor''s Business Daily
Relmada stock crashed Thursday after its depression treatment failed a final-phase test, helping bolster rival Axsome. AXSM stock surged.
Axsome Therapeutics Inc. (AXSM): An Important Analyst Insights 2021/10/30 11:30:00 Stocks Register
Axsome Therapeutics Inc. (NASDAQ:AXSM) price on Friday, October 29, fall -2.88% below its previous days close as a downside momentum from buyers pushed the stocks value to $38.50. A look at the stocks price movement, the close in the last trading session was $39.64, moving within a range at $38.10 and $40.81. The beta value Axsome Therapeutics Inc. (AXSM): An Important Analyst Insights Read More »
Axsome Therapeutics Inc (AXSM): Price Now Near $40.33; Daily Chart Shows An Uptrend on 50 Day Basis 2021/10/29 15:21:47 ETF Daily News
The Hourly View for AXSM At the time of this writing, AXSM (Get Ratings)s price is up $0.22 (0.55%) from the hour prior. The hourly chart shows that AXSM has seen 2 straight up hours. If youre a trader with a preference for rangebound markets, you may wish to note that there isnt a clear [] The post Axsome Therapeutics Inc (AXSM): Price Now Near $40.33; Daily Chart Shows An Uptrend on 50 Day Basis appeared first on ETF Daily News .
Alethea Capital Management LLC Has $68.20 Million Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) 2021/10/27 15:22:52 Transcript Daily
Alethea Capital Management LLC decreased its holdings in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) by 0.1% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,010,945 shares of the companys stock after selling 1,258 shares during the period. Axsome Therapeutics makes []
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Given Consensus Recommendation of Buy by Analysts 2021/10/21 08:00:42 Dakota Financial News
Axsome Therapeutics, Inc. (NASDAQ:AXSM) has been given a consensus recommendation of Buy by the thirteen ratings firms that are currently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold rating and twelve have assigned a buy rating to the company. The average twelve-month target price among brokers []